Abstract Library

#4612 Intraoperative beta-probe for pathological tissue detection in GEP-NET patients: A prospective phase II trial

Introduction: Accurate localisation of gastroenteropancreatic neuroendocrine tumours (GEP-NET) is essential for successful radical surgery. Radio guided surgery (RGS) is an innovative technique that may enhance lesion detection.

Conference:

Presenting Author: Bertani E

Authors: Bertani E, Fumagalli Romario U, Collamati F, Ferrari M, Mattana F,

Keywords: radio guided surgery, surgery, neuroendocrine tumour, GEP-NET, gastrointestinal tumour,

#4437 Pancreatic metastases in neuroendocrine neoplasia: A systematic review

Introduction: Neuroendocrine neoplasias (NENs) are a heterogeneous group of neoplasms that often metastasise to distant organs, with the liver and bones as common targets. However, metastases to the pancreas are uncommon, accounting for 2–5% of pancreatic malignancies.

Conference:

Presenting Author:

Authors: Rinzivillo M, Romano E, Dell' Unto E, Marasco M, Panzuto F,

Keywords: pancreatic metastasis, 68Gallium-PET, incidence,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4133 Clinical impact and prognosis of patients with Si-NET and bone metastases – Do they matter?

Introduction: The prevalence of bone metastases (BM) in small intestinal neuroendocrine tumors (Si-NET) ranges from 5 to 23 %.

Conference:

Presenting Author: Wedin M

Authors: Wedin M, Daskalakis K, Tiensuu Janson E, Sundin A, Wallin G,

Keywords: bone metastases, si-net, Neuroendocrine Neoplasm,

#4045 Radio-guided surgery with a new generation β-probe for radiolabelled somatostatin analogue, in patients with small intestinal neuroendocrine tumors – A Phase II surgical trial

Introduction: Radio-guided surgery (RGS) proved to be promising in neuroendocrine tumors (NETs). Previous studies showed high sensitivity but low specificity using gamma probes to detect radiation emitted by radio-labelled somatostatin analogues.

Conference:

Presenting Author: Danieli M

Authors: Bertani E, Fumagalli Romario U, Collamati F, Mattana F, Fazio N,

Keywords: Radio-guided surgery, small-intestinal neuroendocrine tumor, small-intestinal resection, beta-probe, radiolabelled somatostatine analogues, surgery, lymphadenectomy,